Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.51 |
| ▸ | ALB | P02768 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | EPOR | P19235 | 1/20 | 0.36 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.35 |
| ▸ | CCKAR | P32238 | 3/20 | 0.34 |
| ▸ | CCKBR | P32239 | 3/20 | 0.34 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12972437 | 0.94 | GLP1R (0.47) | GLP1RALBTSHREPORFOLH1 | |
| SCHEMBL12972442 | 0.94 | GLP1R (0.47) | GLP1RALBTSHREPORFOLH1 | |
| SCHEMBL8119857 | 0.93 | GLP1R (0.44) | GLP1RALBTSHREPORFOLH1 | |
| SCHEMBL8116035 | 0.92 | GLP1R (0.50) | GLP1RALBTSHREPORMEN1 | |
| SCHEMBL14550361 | 0.92 | GLP1R (0.56) | GLP1REPORFOLH1CCKARCCKBR | |
| SCHEMBL14550390 | 0.92 | GLP1R (0.56) | GLP1REPORFOLH1CCKARCCKBR | |
| SCHEMBL13577551 | 0.92 | GLP1R (0.56) | GLP1REPORFOLH1CCKARCCKBR | |
| SCHEMBL14550509 | 0.92 | GLP1R (0.56) | GLP1REPORFOLH1CCKARCCKBR | |
| SCHEMBL13539399 | 0.92 | GLP1R (0.46) | GLP1RALBTSHREPORFOLH1 | |
| SCHEMBL12972443 | 0.92 | GLP1R (0.45) | GLP1RALBTSHREPORFOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7854919-B2 | Multivalent constructs for therapeutic and diagnostic applications | Bracco, Suisse SA (CH) | 2010-12-21 | — | — | US | disclosed |
| US-20070243139-A1 | MULTIVALENT CONSTRUCTS FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS | BRACCO INTERNATIONAL B.V. (NL) | 2007-10-18 | — | — | US | disclosed |
| US-7261876-B2 | Multivalent constructs for therapeutic and diagnostic applications | BRACCO INTERNATIONAL BV (NL) | 2007-08-28 | — | — | US | disclosed |
| US-20040210041-A1 | Multimeric proteins for use in the treatment and detection of cell proliferative disorders | ARBOGAST CHRISTOPHE (FR) | 2004-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070243139-A1 | MULTIVALENT CONSTRUCTS FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS | CD47, BCR, CD44 | GLP1R 2595/4885ALB 589/4885TSHR 2125/4885 |
| US-20040210041-A1 | Multimeric proteins for use in the treatment and detection of cell proliferative disorders | MKI67, TP53, VHL | GLP1R 4619/4885ALB 1656/4885TSHR 4153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.